WELL Health's Guidance Raise and WELLSTAR Spinout Signal a Strategic Inflection Point

Strategic Execution, Higher Guidance

WELL Health's Q2 2026 report is less about a single beat and more about a decisive strategic inflection. The company crossed its EBITDA milestone for WELL Canada three quarters ahead of plan, and management promptly raised full‑year 2026 adjusted EBITDA guidance to C$185M–C$195M from C$175M–C$185M. “We reached our CAD 100 million adjusted EBITDA run rate milestone for WELL Canada three quarters ahead of schedule and at margins meaningfully ahead of our original expectations.” — Hamed Shahbazi, Chairman and Chief Executive Officer · 2026-08-06 That milestone, combined with the bond offering that pushed debt maturities to 2031 and a fully funded WELLSTAR listing on the TSX Venture Exchange, is the backdrop for the raised outlook.

We are building a larger, higher quality, better capitalized healthcare platform, one that is delivering stronger profitability today while creating multiple avenues for future growth.

Revenue in the quarter grew 12% to ~C$400M, but adjusted EBITDA on a reported basis fell 3% to C$48.1M due to one‑time items and Circle Medical deferrals. Normalized growth was stronger: adjusted EBITDA +8%, and June alone showed normalized growth of +43%. The exit rate underpins the upgrade.

WELLSTAR: A Growth Platform Goes Public

WELLSTAR’s planned standalone listing is a pivotal capital allocation event. The company raised C$50M (primary + secondary) at a point where it is generating ~C$95M in 2026 revenue at a ~21% adjusted EBITDA margin, with a three‑year organic growth target above 20%. “WELLSTAR is expected to begin trading on the TSX Venture Exchange in September.” — Hamed Shahbazi, Chairman and Chief Executive Officer · 2026-08-06 The spinout frees WELL Health to focus capital on its Canadian clinic network while giving WELLSTAR its own currency for AI‑driven product innovation and strategic acquisitions. This creates a cleaner investment narrative and aligns with the broader trend of tech‑enabled healthcare listings.

Canadian Clinics: Higher‐Margin Expansion

The Canadian clinic business is the core growth engine, with WELL Canada revenue up 32% (41% ex one‑time items) and adjusted EBITDA up 19% (56% ex items) in Q2. The diagnostic business is a focal point, reinforced by the acquisitions of Ontario Imaging Diagnostics (OID) and UnionMD, which add ~C$22M in annual EBITDA. These are exactly the higher‑margin, higher‑growth assets management prefers. “We completed two highly strategic acquisitions, Ontario Imaging Diagnostics and UnionMD, which expand our leadership in Canadian outpatient healthcare while adding approximately CAD 22 million of annual EBITDA.” — Hamed Shahbazi, Chairman and Chief Executive Officer · 2026-08-06 The clinic transformation team is also shifting toward absorptions and organic provider recruitment, improving per‑provider productivity. The new target: WELL Canada to exceed a C$1B revenue run rate by 2028, and WELL Clinics alone to clear C$100M in adjusted EBITDA by year‑end.

Operational Leverage and AI Enablement

Technology enablement remains the key differentiator. Patient visits per billable provider rose to ~576 (from ~449 two years ago), driven by AI transcription and digital workflows. The company’s care interactions grew 21% (11% organic), showing the technology layer is doing more alongside clinicians. “AI transcription and digital workflows remain a key driver of that productivity gain.” — Hamed Shahbazi, Chairman and Chief Executive Officer · 2026-08-06 This is a replicable efficiency play that supports margin expansion without sacrificing quality.

At the same time, the strategic review of U.S. assets (CRH Medical, Wisp, Circle Medical) continues with 10+ parties engaged. Management framed the proceeds as a means to fund Canadian clinic growth and the WELLSTAR roadmap. While the Competition Bureau review remains an overhang, the company reiterates its confidence.
Overall, this quarter shows a company moving from aggregation to integration — every pillar (clinics, WELLSTAR, HEALWELL) is advancing, and the capital structure now supports the next leg. The raised guidance is a tangible signal that execution is ahead of plan.